Decoy Therapeutics (DCOY)
Developer of peptide-conjugate antivirals against shared viral fusion machinery.
Something off on this page? Send us feedback.
Designs preclinical peptide-conjugate antivirals that seek to block shared viral entry machinery across respiratory and other enveloped viruses. Funds development through equity and grants, using IMP³ACT to pair computational design, synthesis, and testing while relying on external partners.
Develops peptide-conjugate Designable Multi-Antivirals that target shared viral fusion machinery across enveloped-virus families. The IMP³ACT platform combines computational structure and binding models, AI/ML-assisted optimization, rapid synthesis, and antiviral assays in a design-build-test-learn loop. Its lead DCOY-CoV program targets broad coronavirus prevention, while DCOY-TRI explores influenza, coronavirus, and RSV/paramyxovirus coverage; filovirus and arenavirus work is exploratory.
Operates from Houston with offices in Cambridge and laboratory space in Long Island City, relying on external manufacturers, CROs, laboratories, computational vendors, and hVIVO for development execution. With no approved products or sales, funding comes from equity financing and restricted grants. All D-MAV candidates remain preclinical, and progress depends on candidate selection, testing, manufacturing, regulatory acceptance, clinical development, and financing.
Company facts
No analyst consensus on record.
EPSReportedEstimate
RevenueReportedEstimate
Balance sheet, Jun 30, 2026Cash & short-term investments $8.3M · Total debt $0 · Total assets $9.0M · Shareholders' equity $4.3M
- Revenue
- $0
- Operating income
- −$2.6M
- Net income
- −$2.4M
No dividends on record.
| Institutions4 holders · as of Mar 31, 2026 | 0.25% | 1.6K shares | |
| Insiders10 holders · as of Sep 2, 2026 | 10.56% | 69.2K shares | |
| Strategic holders1 holder · as of Aug 14, 2026 | 10.00% | 65.5K shares | |
| Otherremainder | 79.19% | 518.9K shares |
655.2K company shares as of Sep 3, 2026 · institutions as of Mar 31, 2026 · holders as of their latest filing
Two share counts disagree (655.2K in the company's Sep 3, 2026 report, 532.0K elsewhere); stakes use the report.
A stock split fell inside the quarter, so quarter-on-quarter changes are not shown.
Top shareholders13F · 13D/G · Form 4
| Holder | Stake | Shares | Evidence |
|---|---|---|---|
Armistice Capital, LLCStrategic | 10.00% | 65,503 | 13Gfiled Aug 14, 2026 ↗ |
Frederick Ii PierceInsiderofficer: Chief Executive Officer | 5.32% | 34,844 | Form 4filed Sep 2, 2026 ↗ |
Mark J. RosenblumInsiderofficer: Chief Financial Officer | 1.73% | 11,363 | Form 4filed Sep 2, 2026 ↗ |
Barbara Louise HibnerInsiderofficer: Chief Scientific Officer | 0.64% | 4,216 | Form 4filed Sep 2, 2026 ↗ |
Peter Klaus MarschelInsiderofficer: Chief Business Officer | 0.60% | 3,900 | Form 4filed Sep 2, 2026 ↗ |
| See all 25 → | |||
13D/13G — an ownership statement filed at 5% or more · Form 4 — an insider's transaction report
Insider tradesForm 4
| Date | Insider | Role | Shares | Avg price |
|---|---|---|---|---|
| Dec 30, 2025 | Arnold C. Hanish | director | −27 | $0.6397 |
| Nov 20, 2025 | Arnold C. Hanish | director | +5,000 | $0.7481 |
| Nov 20, 2025 | Mark J. Rosenblum | officer: Exec VP Finance, CFO | +20,000 | $0.8000 |
- Pfizer
Approved and late-stage oral COVID antivirals for high-risk patients.
- Merck
Long-acting influenza prevention challenges DCOY-TRI in high-risk patients.
- Invivyd
Phase 3 COVID antibody prevention overlaps the high-risk prophylaxis market.
- Traws Pharma
Phase 2 ritonavir-free COVID treatment overlaps early-use positioning.
ComparePre-market
| Company | Price | Change | |||||
|---|---|---|---|---|---|---|---|
| Decoy Therapeutics | $2.82 | −5.69% | $1.6M | — | — | — | — |
| Pfizer | $28.96 | −0.24% | $165.40B | 38.3 | 10.4 | 2.6 | +2.6% |
| Merck | $151.96 | +0.21% | $374.52B | 121.3 | 17.6 | 5.6 | +5.1% |
| Invivyd | $0.8596 | +6.58% | $236.9M | — | — | 4.1 | +21.2% |
| Traws Pharma | $0.5800 | +1.79% | $8.7M | — | — | — | — |
| Median | 79.8 | 14.0 | 4.1 | +5.1% |